Methotrexate, mitoxantrone, 5-Fluorouracil and leucovorin in metastatic breast cancer patients

L. Merlini, V. Secondo, S. Mammoliti, P. Bellotti, C. Castello, L. Gallo

Research output: Contribution to journalArticlepeer-review


We have evaluated the efficacy and toxicity of a chemotherapy consisting of methotrexate, mitoxantrone, 5-Fluorouracil and leucovorin in 21 advanced breast cancer patients. Among 20 evaluable patients, objective response was obtained in 6 patients (30%) with two complete responses, stable disease in 4 patients (20%), while 10 patients (50%) progressed. Median progression-free survival and survival were 10 and 15 months, respectively. The most frequently observed side-effects were myelosuppression and emesis; one patient, who had previously received doxorubicin at the maximum dose-limiting cardiac toxicity, died of congestive heart failure after the third cycle. This treatment is moderately effective for advanced breast cancer patients.

Original languageEnglish
Pages (from-to)1423-1425
Number of pages3
JournalAnticancer Research
Issue number3 B
Publication statusPublished - 1994


  • Biochemical modulation
  • Breast cancer
  • Salvage treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Methotrexate, mitoxantrone, 5-Fluorouracil and leucovorin in metastatic breast cancer patients'. Together they form a unique fingerprint.

Cite this